DexCom, Inc.
NMS: DXCMLive Quote
📈 ZcoreAI Score
Our AI model analyzes DexCom, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get DXCM Z-Score →About DexCom, Inc.
Healthcare
Medical Devices
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
📊 Fundamental Analysis
DexCom, Inc. demonstrates a healthy profit margin of 17.9%.
The company recently reported 13.1% revenue growth, which is above average for the Healthcare sector.
Return on Equity (ROE) is 34.5%, which reflects exceptional capital efficiency.
At a current price of $64.02, DXCM currently sits at the 28th percentile of its 52-week range (Range: $54.11 - $89.98).
💰 Valuation Insight
DXCM is valued broadly in line with the sector at a PE of 30.63. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
⚠️
Profit Margin
Moderate
⚠️
Debt/Equity
Moderate
✅
Revenue Growth
Excellent
✅
Return on Equity
Excellent
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$24.97B
Trailing P/E
30.63
Forward P/E
21.39
Beta (5Y)
1.56
52W High
$89.98
52W Low
$54.11
Avg Volume
4.70M
Day High
Day Low